GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably heard of them under brand names like Ozempi​​c® and Wegovy® (semaglutide) or Monjouro and Zepbound (tirzepatide).

Substance use disorders (SUDs) are a major public health concern, with opioid use disorder (OUD) and alcohol use disorder (AUD) being particularly prevalen | Neuroscience

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, rates of bariatric surgeries dropped by 25%, while prescriptions for weight-loss drugs more than doubled.

The number of adults diagnosed with diabetes has more than quadrupled since 1990 and now stands above 800 million, according to new data released in The Lancet on World Diabetes Day.

Dr. Darien Sutton and Dr. Stephanie Widmer discuss new studies, which found GLP-1 weight loss drugs beneficial in fighting Type 2 diabetes and certain addiction disorders.

Obesity has been declared a disease by WHO. It is associated not only with heart disease, diabetes, stroke, gallstones, osteoarthritis knees but also has mental ramifications.